@prefix dc1: . @prefix this: . @prefix sub: . @prefix np: . @prefix rdf: . @prefix nt: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix bl: . @prefix nkg: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { bl:category bl:Disease . sub:association rdf:object ; rdf:predicate bl:treats; rdf:subject ; a rdf:Statement; rdfs:label "pulmozyme r in cf patients with an fvc 4 of predicted daily administration of pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics pulmozyme is a recombinant dnase enzyme indicated in conjunction with standard therapies for the management of cystic fibrosis cf patients to improve pulmonary function 1"; bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation; bl:provided_by ; bl:relation nkg:SymptomaticReliefIndication . bl:category bl:Drug . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "apKQ2rdv9oREBCIc38cNFSQq39Toq5OAudEPVCF+uGJpRLVhiAZfxGfNuf4PLPGiaSy/YI/MUHZeALMqVgvgtL8zuYTxrZhANmSidCv8MkXlrKiHuzoLnyYwvbQypOuQUqXJFdZOeRO5LKL5qdUmwlnaMZbew1Wu0daUK8U0aSk="; npx:hasSignatureTarget this: . this: dc1:created "2021-06-12T12:30:51.524+02:00"^^xsd:dateTime; dc1:creator orcid:0000-0002-1468-3557; nt:wasCreatedFromProvenanceTemplate ; nt:wasCreatedFromPubinfoTemplate ; nt:wasCreatedFromTemplate . }